Mineralys Therapeutics to Participate in the Wells Fargo Healthcare Conference

Rhea-AI Summary

Mineralys Therapeutics (NASDAQ: MLYS), a clinical-stage biopharmaceutical company, has announced its participation in the Wells Fargo Healthcare Conference in Boston, MA from September 4-6, 2024. The company's management will engage in a fireside chat on Thursday, September 5, 2024, at 1:30pm EDT.

Mineralys focuses on developing medicines for hypertension, chronic kidney disease (CKD), and other aldosterone-related disorders. Investors and interested parties can access a live webcast of the fireside chat through the company's website under the 'News and Events' section of Investor Relations. A replay will be available for approximately 90 days after the event.

News Market Reaction – MLYS

-0.66%

-0.66% Session move

In the trading session that priced this news, MLYS declined 0.66%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RADNOR, Pa., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in a fireside chat at the Wells Fargo Healthcare Conference, being held in Boston, MA on September 4-6, 2024.

Wells Fargo Healthcare Conference
Date: Time: Format: Webcast Link	Thursday, September 5, 2024 1:30pm EDT Fireside Chat

A live webcast of the fireside chat can be accessed under “News and Events” on the Investor Relations section of the Mineralys website at www.mineralystx.com. A replay of the fireside chat will be available on the Company’s website for approximately 90 days.

About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by dysregulated aldosterone, including hypertension and CKD. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.

Contact:

Investor Relations
investorrelations@mineralystx.com

Media Relations
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: tweible@elixirhealthpr.com

FAQ

When is Mineralys Therapeutics (MLYS) participating in the Wells Fargo Healthcare Conference?

Mineralys Therapeutics (MLYS) is participating in the Wells Fargo Healthcare Conference on Thursday, September 5, 2024, at 1:30pm EDT.

What format will Mineralys Therapeutics' (MLYS) presentation take at the Wells Fargo Healthcare Conference?

Mineralys Therapeutics' (MLYS) presentation at the Wells Fargo Healthcare Conference will be in the format of a fireside chat.

How can investors access Mineralys Therapeutics' (MLYS) presentation at the Wells Fargo Healthcare Conference?

Investors can access a live webcast of Mineralys Therapeutics' (MLYS) fireside chat through the company's website under the 'News and Events' section of Investor Relations.

What medical conditions does Mineralys Therapeutics (MLYS) focus on in its drug development?

Mineralys Therapeutics (MLYS) focuses on developing medicines for hypertension, chronic kidney disease (CKD), and other diseases driven by dysregulated aldosterone.